The White House's Cannabis Contradiction: Rescheduling with One Hand, Criminalizing with the Other

On May 4, the Office of National Drug Control Policy released the 2026 National Drug Control Strategy, a 180-page blueprint for the administration's approach to the drug crisis. The document is overwhelmingly focused on fentanyl, cartel dismantlement, and synthetic opioids — and for good reason. Over 72,000 Americans died from drug overdoses in the twelve months ending August 2025, and illicit fentanyl remains the primary driver.

But buried in Chapter 1, under the heading "Domestic Production," the Strategy makes a choice that should concern every cannabis operator, investor, and advocate in the country. It lists "high-potency marijuana grown by criminal groups" and "unregulated psychoactive derivatives of hemp" alongside tianeptine, kratom, and Amanita muscaria mushrooms as domestic threats "exploiting legal and regulatory loopholes." Later, the introduction singles out "psychoactive derivatives of hemp packaged as candies or vapes" as products that "prey on young Americans."

That's the entirety of the Strategy's cannabis engagement. No acknowledgment of the 40-plus state regulatory frameworks governing legal cannabis markets. No mention of the 300,000 jobs in the hemp economy. No reference to the medical marijuana program that, as of eleven days prior, the administration's own Department of Justice moved to Schedule III.

Two agencies, two realities

On April 23, Acting Attorney General Todd Blanche signed a final order reclassifying FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. The order was the most significant federal shift on marijuana policy in decades. It acknowledged medical utility, opened banking pathways, and — critically for operators — eliminated Section 280E tax penalties for state-licensed medical marijuana businesses that had been paying effective tax rates north of 70 percent.

Eleven days later, ONDCP published a Strategy whose stated vision is "a safe and healthy America, where a drug-free life is the prevailing norm." The Strategy doesn't distinguish between a cartel-grown marijuana crop in a California national forest and a state-licensed dispensary in Colorado that files quarterly tax returns. Both fall under "domestic production" threats.

This isn't an oversight. It's a structural tension baked into federal law. ONDCP is statutorily required to oppose drug legalization under 21 U.S.C. § 1703. There's actually a bill alive in the current Congress — the bipartisan measure to repeal that requirement — but until it passes, the Drug Czar's office is legally obligated to frame all Schedule I and II substances as threats, regardless of what DOJ is doing on the rescheduling front. The Strategy is ONDCP doing what the statute tells it to do.

But that doesn't make the contradiction less consequential for the industry.

The hemp loophole closure tightens the vise

The Strategy's specific callout of hemp-derived THC products lands in a market that's already bracing for a seismic regulatory shift. In November 2025, Congress enacted legislation rewriting the federal definition of hemp, replacing the narrow delta-9 THC standard from the 2018 Farm Bill with a total THC metric and a strict 0.4 milligram per-container cap. The new definition takes effect November 12, 2026.

When it does, the delta-8 and THCA product categories that generated billions in revenue through the Farm Bill's loophole will become Schedule I controlled substances overnight. Products that are currently sold legally in gas stations and smoke shops across the country will carry the same federal classification as heroin.

The Strategy's language targeting "psychoactive derivatives of hemp packaged as candies or vapes" reads like a policy endorsement of that legislative crackdown. ONDCP is laying the rhetorical groundwork for enforcement actions that the November deadline makes legally possible.

June 29: The next inflection point

The real action happens in less than two months. The DEA has scheduled administrative law hearings for June 29 to address what the agency calls the "adult-use gap" — whether the medical-use findings that justified the April rescheduling can be extended to cover the entire cannabis plant regardless of end-user intent.

DOJ has reportedly signaled a desire to harmonize regulations by mid-July to avoid a fractured federal enforcement framework between medical and recreational programs. If that hearing produces a favorable outcome, adult-use cannabis could follow medical marijuana to Schedule III, fundamentally reshaping the federal landscape.

But the Strategy released today suggests ONDCP isn't aligned with that trajectory. A document that frames marijuana as a domestic production threat and champions "drug-free America as the social norm" doesn't read like an administration preparing to normalize adult-use cannabis at the federal level.

What this means for the sector

For multi-state operators and the publicly traded cannabis companies tracked by MSOS, the picture is genuinely mixed. The Schedule III medical rescheduling is real and material — Section 280E relief alone could add hundreds of millions in retained earnings across the sector. Banking access, while not fully resolved without SAFE Banking legislation, becomes incrementally easier under Schedule III.

But the NDCS signals that the broader federal posture hasn't caught up to the legal reality. ONDCP's $44 billion budget and coordination authority across 19 federal agencies means its framing matters, even when it conflicts with DOJ's actions. Agencies take cues from the Strategy when allocating enforcement resources and setting priorities.

The practical read: medical operators are in a materially better position than they were a month ago. Adult-use operators remain in regulatory limbo until the June 29 hearing clarifies DOJ's intent. And hemp-derived THC companies face an existential deadline in November that the Strategy appears to endorse rather than moderate.

The cannabis industry has learned to live with federal contradictions. This one is just louder than most.